Ian Chau

Ian Chau, MD, FRCP is Consultant Medical Oncologist and Professor of Gastrointestinal Oncology at the Royal Marsden Hospital and the Institute of Cancer Research in London. He is a leading European expert in esophageal, gastroesophageal junction, and gastric cancer, recognized for his extensive clinical trial portfolio spanning immunotherapy, targeted therapy, and perioperative treatment in upper GI malignancies. Dr. Chau was a co-investigator in multiple landmark trials including KEYNOTE-590 (pembrolizumab in esophageal cancer), KEYNOTE-811 (pembrolizumab plus trastuzumab and chemotherapy in HER2+ gastric cancer), and CheckMate 649. He has led numerous investigator-initiated trials at the Royal Marsden examining biomarker-driven approaches and combination immunotherapy strategies. Dr. Chau's translational research program has focused on genomic heterogeneity, ctDNA dynamics, and immune microenvironment characterization in esophagogastric cancers, identifying predictors of response and resistance to checkpoint inhibitors. He is an active contributor to ESMO clinical practice guidelines and educational faculty for upper GI oncology at ASCO, ESMO, and WCGIC. Dr. Chau is also a pioneer in early clinical development of anti-claudin 18.2 therapies in gastric cancer at European sites.